Literature DB >> 6332444

Effects of ovine corticotrophin-releasing factor and hydrocortisone on growth hormone secretion by pituitary adenoma cells of acromegaly in culture.

M Ishibashi, T Hara, Y Tagusagawa, T Fukushima, H Numata, T Hori, T Yamaji.   

Abstract

In an attempt to test the hypothesis that pituitary adenomas of acromegaly may possess altered cellular membrane receptors, the response of growth hormone (GH) secretion to ovine corticotrophin-releasing factor (CRF) in cultured adenoma cells of acromegaly was studied. In three out of seven experiments using different pituitary adenoma cells in culture, nanomolar concentrations of CRF caused a significant increase in GH release. The CRF-induced GH release was reproducible and a dose-response relationship was observed between the CRF concentrations and the amounts of GH released into the incubation media. Hydrocortisone, at a concentration of 1 microM, on the other hand, resulted in a significant decrease in GH secretion in four out of five experiments. When adenoma cells were co-incubated with CRF and 1 microM hydrocortisone, CRF-induced GH release was partially overcome. In one experiment, the inhibitory effect of hydrocortisone was reversed by co-incubation with CRF, although CRF alone was ineffective in the stimulation of GH. These results suggest that CRF may stimulate GH release in some, though not all, patients with acromegaly, and that glucocorticoids may block this effect of CRF acting directly on the pituitary adenoma cells of acromegaly.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332444     DOI: 10.1530/acta.0.1060443

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  1 in total

1.  Plasma growth hormone (GH) responses to corticotropin-releasing hormone in patients with acromegaly--the effect of dexamethasone pretreatment and the comparison with GH responses to thyrotropin-releasing hormone, gonadotropin-releasing hormone and GH-releasing hormone.

Authors:  A Utsumi; K Hanew; A Sugawara; Y Shimizu; O Murakami; H Ikeda; K Yoshinaga
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.